Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024
July 29 2024 - 4:05PM
Spero Therapeutics, Inc. (Nasdaq: SPRO), a
multi-asset clinical-stage biopharmaceutical company, focused on
identifying and developing novel treatments for rare diseases and
multi-drug resistant (MDR) bacterial infections, today announced
that management will host a conference call and live audio webcast
on Monday August 5th, 2024 at 4:30 p.m. ET to report financial
results for second quarter 2024 and provide an update on its
business and pipeline.
To access the call, please dial 1-877-269-7751
(domestic) or 1-201-389-0908 (international) and refer to
conference ID 13747505, or click on this link and
request a return call. The audio webcast can be accessed live on
this link and also on the “Investor Relations”
page of the Spero Corporate Website at
https://sperotherapeutics.com.
The archived webcast will also be available on Spero’s website for
30 days following the call.
About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge,
Massachusetts, is a multi-asset, clinical-stage biopharmaceutical
company focused on identifying and developing novel treatments for
rare diseases and multi-drug resistant (MDR) bacterial
infections. For more information -
www.sperotherapeutics.com
Investor Relations Contact: Shai Biran,
PhDSpero TherapeuticsIR@Sperotherapeutics.com
Media Inquiries:media@sperotherapeutics.com
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From Dec 2024 to Jan 2025
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From Jan 2024 to Jan 2025